Subcutaneous Dexpanthenol Administration and Wound Epithelialization

Starting soon · Not applicable

Conditions studied: Chronic Wounds, Diabetic Foot Ulcer, Venous Leg Ulcers, Arterial Ulcer

In brief

Chronic wounds are wounds that do not heal properly over time and can significantly reduce quality of life. Common types include diabetic foot ulcers, venous leg ulcers, and arterial ulcers. Improving wound healing and speeding up skin regeneration (epithelialization) are important goals in the care of these patients. Dexpanthenol is a vitamin B5 derivative that supports skin repair and tissue regeneration. It is widely used in topical treatments, and injectable forms are approved for clinical use. However, the effects of subcutaneous (under the skin) dexpanthenol injections on chronic wound healing have not been sufficiently studied in clinical settings. The purpose of this study is to evaluate whether adding subcutaneous dexpanthenol injections to standard wound care improves wound healing compared with standard wound care alone. Adult patients with non-infected chronic wounds will be randomly assigned to one of two groups. One group will receive standard wound care only, while the other group will receive standard wound care plus subcutaneous dexpanthenol injections around the wound area. Wound healing will be assessed by measuring changes in wound size and the degree of skin epithelialization over time using standardized and objective methods. Safety will be monitored by recording local reactions at the injection site and any other adverse events during the study. The results of this study may provide preliminary clinical evidence on the effectiveness and safety of subcutaneous dexpanthenol as an additional treatment option for chronic wound management.

Key facts

Study ID

NCT07395674

Run by

Dilara CANBAY OZDEMIR

People needed

40

Starts

2026-08-02

Expected to finish

2028-12-02

Last updated by the study team

2026-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 years and older.
• Presence of a chronic wound, including diabetic foot ulcer, venous leg ulcer, or arterial ulcer.
• Target wound size between 1 and 20 cm² at baseline.
• Non-infected wound, defined by the absence of purulent discharge, foul odor, spreading erythema, cellulitis, or systemic signs of infection.
• Clinically stable patients without the need for systemic antibiotic therapy.
• Ability to understand the study procedures and provide written informed consent.
• Willingness and ability to comply with study visits and treatment schedule.

You may not qualify if…

• Clinical signs of wound infection or requirement for systemic antibiotic treatment.
• Critical limb ischemia, defined as ankle-brachial index <0.5, rest pain, gangrene, or extensive tissue necrosis.
• Wounds exposing bone, tendon, or joint structures, or suspected osteomyelitis.
• Wound size smaller than 1 cm² or larger than 20 cm².
• Malignant, autoimmune, vasculitic, or specific dermatologic conditions causing the wound.
• Known hypersensitivity or allergy to dexpanthenol or any component of the study treatments.
• Pregnancy or breastfeeding.
• Cognitive impairment or inability to provide informed consent.
• Participation in another interventional clinical trial that could interfere with the outcomes of this study.
• Any medical condition that, in the investigator's judgment, could compromise participant safety or study integrity.

Where it is running

• Ordu University Training and Research Hospital — Ordu, Ordu, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.